Study of the tolerability of the vaginal ring (NuvaRing®) in contraception (ETN@);Estudio de eficacia y tolerabilidad del anillo vaginal (NuvaRing®) en anticoncepción (ETN@)

Progresos en Obstetricia y Ginecologia

Volumn 49, Issue 12, 2006, Pages 695-700

  Lete Lasa, Iñaki ^a   Borrego, Rafael Sánchez ^b   Palazuclos, Javier Haya ^c  

^a HOSPITAL TXAGORRITXU   (Spain)

^b Clinica Diatros   (Spain)

^c HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

Author keywords

Contraceptive vaginal ring; Intermenstrual bleeding; Tolerability

Indexed keywords

EID: 34249077857     PISSN: 03045013     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-5013(06)72673-5     Document Type: Article

References (7)

1. Heuvel MW, Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestraidiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005; 72:168-74.
2. What women want: internacional survey of birth control methods. What do American women want? Pharmacia Corporation 2000. Disponible en: http://www.birthcontrolresourccs.com
3. Roumen FJME, Apter D, Mulders TMT, Dieben TOM. Efficacy, tolerability and acceptability of a novel contraceptive vaginalring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;l6:469-75.
4. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuses of oral contraceptives: risk indicators for poor pill-taking and discontinuations. Contraception. 1995;51:283-8.
5. Equipo Daphne. El cumpllmlento en anticonccpción hormonal oral en España. Madrid: Aula Médica; 2000. p. 47.
6. Dieben TOM, Koumen FJME, Apter D. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100:585-93.
7. Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233-42.